



## WAVE Life Sciences to Present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable

September 14, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 14, 2016-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, today announced that Paul Bolno, M.D., MBA, President and Chief Executive Officer, will participate in a fireside chat and provide a company overview at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable on Wednesday, September 28, 2016, at 9:00 A.M. ET in New York, NY.

### About WAVE Life Sciences

At WAVE Life Sciences, we are driven by an unwavering passion and commitment to deliver on our mission of confronting challenging diseases by developing transformational therapies and empowering patients. We are utilizing our innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare and other serious genetically defined diseases. Given the versatility of our chemistry platform, WAVE's deep, diverse pipeline spans multiple modalities including antisense, exon-skipping, and single-stranded RNAi. For more information, please visit [www.wavelifesciences.com](http://www.wavelifesciences.com) and follow us on Twitter at @WAVELifeSci and LinkedIn.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20160914005248/en/>

Source: WAVE Life Sciences

### Investor Contact:

WAVE Life Sciences  
Jillian Connell, 617-949-2981  
[jconnell@wavelifesci.com](mailto:jconnell@wavelifesci.com)

or

### Media Contact:

Feinstein Kean Healthcare  
Jess Rowlands, 202-729-4089  
[jessica.rowlands@fkhealth.com](mailto:jessica.rowlands@fkhealth.com)